Jônatas Sousa Pires dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jônatas Sousa Pires dos Santos has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Valeria Campos de Souza
Laboratory of Molecular Modeling and Computational Structural Biology, Walter Mors Natural Products Research Institute, Health Sciences Center, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-599, Brazil
1 shared publication - Cássio Santana Meira
Instituto Gonçalo Moniz Fundação Oswaldo Cruz (FIOCRUZ) Salvador Bahia Brazil
1 shared publication - Dahara Keyse Carvalho Silva
Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Fiocruz, Salvador 40296-710, Brazil
1 shared publication - Edivaldo dos Santos Rodrigues
Laboratory of Molecular Modeling and Computational Structural Biology, Walter Mors Natural Products Research Institute, Health Sciences Center, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-599, Brazil
1 shared publication - Milena Botelho Pereira Soares
Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador 40296-710, BA, Brazil
1 shared publication - Osvaldo Andrade Santos Filho
Instituto de Pesquisas de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
1 shared publication
Latest Publications
- Open Access
- 29 May 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (6) , 232
The Alkaloid Caulerpin Exhibits Potent and Selective Anti-Inflammatory Activity Through Interaction with the Glucocorticoid Receptor
Inflammation plays a central role in various pathological conditions, necessitating the search for safer and more effective anti-inflammatory agents. This study investigates the anti-inflammatory activity of caulerpin, a bisindolic alkaloid isolated from Caulerpa racemosa. In vitro assays demonstrated that caulerpin significantly reduced nitric oxide, TNF-α, IL-6, and IL-12 levels in macrophages stimulated with LPS + IFN-γ, without affecting cell viability. In silico toxicity predictions using Protox 3.0 reinforce a favorable safety profile of caulerpin. Molecular docking and molecular dynamics simulations revealed its high-affinity binding to the glucocorticoid receptor ligand-binding domain (GR-LBD), suggesting a mechanism of action similar to dexamethasone. The involvement of the glucocorticoid receptor was confirmed by the partial reversal of caulerpin’s effects upon RU486 treatment. In vivo, caulerpin exhibited a favorable safety profile, with no signs of acute toxicity at an oral dose of 100 mg/kg. Moreover, in a mouse model of endotoxic shock, caulerpin administration significantly improved survival rates in a dose-dependent manner, providing complete protection at 4 mg/kg. These findings highlight caulerpin as a promising candidate for the development of novel anti-inflammatory therapies. Further studies are warranted to explore its pharmacokinetics, optimize its structure, and evaluate its efficacy in chronic inflammatory diseases.
- 29 May 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (6) , 232
Open AccessThe Alkaloid Caulerpin Exhibits Potent and Selective Anti-Inflammatory Activity Through Interaction with the Glucocorticoid Receptor
Inflammation plays a central role in various pathological conditions, necessitating the search for safer and more effective anti-inflammatory agents. This study investigates the anti-inflammatory activity of caulerpin, a bisindolic alkaloid isolated from Caulerpa racemosa. In vitro assays demonstrated that caulerpin significantly reduced nitric oxide, TNF-α, IL-6, and IL-12 levels in macrophages stimulated with LPS + IFN-γ, without affecting cell viability. In silico toxicity predictions using Protox 3.0 reinforce a favorable safety profile of caulerpin. Molecular docking and molecular dynamics simulations revealed its high-affinity binding to the glucocorticoid receptor ligand-binding domain (GR-LBD), suggesting a mechanism of action similar to dexamethasone. The involvement of the glucocorticoid receptor was confirmed by the partial reversal of caulerpin’s effects upon RU486 treatment. In vivo, caulerpin exhibited a favorable safety profile, with no signs of acute toxicity at an oral dose of 100 mg/kg. Moreover, in a mouse model of endotoxic shock, caulerpin administration significantly improved survival rates in a dose-dependent manner, providing complete protection at 4 mg/kg. These findings highlight caulerpin as a promising candidate for the development of novel anti-inflammatory therapies. Further studies are warranted to explore its pharmacokinetics, optimize its structure, and evaluate its efficacy in chronic inflammatory diseases.